Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.9896
+0.01281.31%
Post-market: 0.9892-0.0004-0.04%19:59 EST
Volume:392.31K
Turnover:383.39K
Market Cap:104.90M
PE:-3.47
High:0.9970
Open:0.9863
Low:0.9601
Close:0.9768
52wk High:1.51
52wk Low:0.3258
Shares:106.00M
Float Shares:93.63M
Volume Ratio:0.56
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.2881
ROE:-769.06%
ROA:-111.21%
PB:1258.27
PE(LYR):-3.43

Loading ...

BRIEF-Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To Nevada

Reuters
·
Yesterday

Oncolytics Biotech Inc - Reschedules Special Meeting to January 15, 2026

THOMSON REUTERS
·
Yesterday

BRIEF-Oncolytics Biotech® Provides Update On Special Meeting Of Shareholders

Reuters
·
Nov 21

Oncolytics Biotech Plans Move from Alberta to Nevada

Reuters
·
Nov 21

Oncolytics Biotech Inc - Special Meeting Rescheduled Due to U.S. Government Shutdown

THOMSON REUTERS
·
Nov 21

Oncolytics Biotech Inc - Cancels and Will Reschedule Special Shareholder Meeting

THOMSON REUTERS
·
Nov 21

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

THOMSON REUTERS
·
Nov 21

Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)

TIPRANKS
·
Nov 20

Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital

TIPRANKS
·
Nov 20

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

Reuters
·
Nov 20

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Nov 19

BUZZ-Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial

Reuters
·
Nov 19

Oncolytics aligns with FDA on pelareorep study design

TIPRANKS
·
Nov 19

BRIEF-Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer

Reuters
·
Nov 19

Oncolytics Biotech® Aligns With FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

THOMSON REUTERS
·
Nov 19

Oncolytics Biotech Inc - to Launch Immunotherapy Trial in Pancreatic Cancer in 2026

THOMSON REUTERS
·
Nov 19

Oncolytics Biotech Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 17

Oncolytics reports updated results from study of pelareorep plus atezolizumab

TIPRANKS
·
Oct 28

Oncolytics Biotech Reports Pelareorep Combo Doubles Response Rate in Advanced Anal Cancer Trial

Reuters
·
Oct 28

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

THOMSON REUTERS
·
Oct 28